Paul Tappenden

All publications

Journal articles

• Keetharuth AD, Gould R, McDermott C, Thompson B, Rawlinson C, Bradburn M, Bursnall M, Kumar P, Turton E, Tappenden P , White D et al (2024) Cost-effectiveness of acceptance and commitment therapy for people living with motor neuron disease, and their health-related quality of life. European Journal of Neurology. View this article in WRRO
• Wheaton L, Poad H, Tappenden P & Bujkiewicz S (2023) PT14 Bayesian Meta-Analysis of Data From Trials of Mixed Patient Populations to Inform Health Economic Models for Patients Harboring a Predictive Biomarker. Value in Health, 26(12), S425-S425.
• Lister J, Paisley S, Tappenden P & Carroll C (2023) HTA283 A Scoping Review of Health Technology Assessment Agency (HTA) and Health Economic (HE) Modelling Guidelines for Identification of Health Economic Model Inputs. Value in Health, 26(12), S375-S375.
• Lister J, Paisley S, Tappenden P & Carroll C (2023) EE632 Identification of Health State Utility Values for Health Economic Models: Empirical Testing of Alternative Search Methods. Value in Health, 26(12), S174-S175.
• Needham KJ, Tappenden P, Gillespie D & Whyte S (2023) MA10.05 Model-based Evaluations of the Cost-effectiveness of Interventions for Lung Cancer: A Systematic Review. Journal of Thoracic Oncology, 18(11), S134-S134.
• Umemneku-Chikere CM, Wheaton L, Poad H, Ray D, Andrade IC, Khan S, Tappenden P, Abrams KR, Owen RK & Bujkiewicz S (2023) Individual participant data from digital sources informed and improved precision in the evaluation of predictive biomarkers in Bayesian network meta-analysis. Journal of Clinical Epidemiology, 164, 96-103.
• Tappenden P, Navega Biz A, Hernández Alava M, Sasso A, Sutton L, Ennis K, Elliott R & Wildman M (2023) A model-based economic analysis of the CFHealthHub intervention to support adherence to inhaled medications for people with cystic fibrosis in the UK. International Journal of Technology Assessment in Health Care, 39(1).
• Murphy P, Glynn D, Dias S, Hodgson R, Claxton L, Beresford L, Cooper K, Tappenden P, Ennis K, Grosso A , Wright K et al (2022) Modelling approaches for histology-independent cancer drugs to inform NICE appraisals : a systematic review and decision-framework. Health Technology Assessment, 25(76), 1-228.
• Burt RK, Tappenden P, Balabanov R, Han X, Quigley K, Snowden JA & Sharrack B (2021) The cost effectiveness of immunoglobulin vs. hematopoietic stem cell transplantation for CIDP. Frontiers in Neurology, 12.
• Srivastava T, Latimer NR & Tappenden P (2021) Estimation of Transition Probabilities for State-Transition Models: A Review of NICE Appraisals. PharmacoEconomics.
• Burt RK, Tappenden P, Han X, Quigley K, Arnautovic I, Sharrack B, Snowden JA & Hartung D (2020) Health economics and patient outcomes of hematopoietic stem cell transplantation versus disease-modifying therapies for relapsing remitting multiple sclerosis in the United States of America. Multiple Sclerosis and Related Disorders, 45.
• Jin H, Tappenden P, Robinson S, Achilla E, Aceituno D & Byford S (2020) Systematic review of the methods of health economic models assessing antipsychotic medication for schizophrenia. PLOS ONE, 15(7). View this article in WRRO
• Jin H, Tappenden P, MacCabe JH, Robinson S & Byford S (2020) Evaluation of the cost-effectiveness of services for Schizophrenia in the UK across the entire care pathway in a single whole-disease model. JAMA network open, 3(5). View this article in WRRO
• Jin H, Tappenden P, Robinson S, Achilla E, MacCabe JH, Aceituno D & Byford S (2020) A systematic review of economic models across the entire schizophrenia pathway. PharmacoEconomics. View this article in WRRO
• Tappenden P, Wang Y, Sharrack B, Burman J, Kazmi M, Saccardi R, Bermejo I, Harvey R, Badoglio M, Farge D & Snowden JA (2020) Evaluating the clinical effectiveness of autologous haematopoietic stem cell transplantation versus disease-modifying therapy in multiple sclerosis using a matching-adjusted indirect comparison: an exploratory study from the Autoimmune Diseases Working Party (ADWP) of the European Society of Bone and Marrow Transplantation (EBMT). Bone Marrow Transplantation, 55(7), 1473-1475.
• Alshreef A, Latimer N, Tappenden P, Wong R, Hughes D, Fotheringham J & Dixon S (2019) Statistical methods for adjusting estimates of treatment effectiveness for patient nonadherence in the context of time-to-event outcomes and health technology assessment: A systematic review of methodological papers. Medical Decision Making. View this article in WRRO
• Tappenden P & Caro JJ (2019) Improving Transparency in Decision Models: Current Issues and Potential Solutions. PharmacoEconomics, 37(11), 1303-1304.
• Harnan S, Tappenden P, Cooper K, Stevens J, Bessey A, Rafia R, Ward S, Wong R, Stein RC & Brown J (2019) Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer: a systematic review and economic analysis. Health Technology Assessment, 23(30). View this article in WRRO
• Tappenden P, Carroll C, Hamilton J, Kaltenthaler E, Wong R, Wadsley J, Moss L & Balasubramanian S (2019) Cabozantinib and vandetanib for unresectable locally advanced or metastatic medullary thyroid cancer: a systematic review and economic model. Health Technology Assessment, 23(8), 1-144. View this article in WRRO
• Tappenden P, Carroll C, Stevens J, Simpson E, Thokala P, Wong R, Wright J & Auer R (2019) Ibrutinib for Treating Waldenström’s Macroglobulinaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics, 37(1), 7-18. View this article in WRRO
• Tappenden P, Simpson E, Hamilton J, Pollard D, Clowes M, Kaltenthaler E, Meiklejohn D & Morley N (2018) Ibrutinib for Treating Relapsed or Refractory Mantle Cell Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics. View this article in WRRO
• Bermejo I, Tappenden P & Youn JH (2017) Response to ‘Comment on “Replicating Health Economic Models: Firm Foundations or a House of Cards?”’. PharmacoEconomics. View this article in WRRO
• Tappenden P, Carroll C, Stevens JW, Rawdin A, Grimm S, Clowes M, Kaltenthaler E, Ingram JR, Collier F & Ghazavi M (2017) Adalimumab for Treating Moderate-to-Severe Hidradenitis Suppurativa: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics, 35(8), 805-815. View this article in WRRO
• Bermejo I, Tappenden P & Youn JH (2017) Replicating Health Economic Models: Firm Foundations or a House of Cards?. Pharmacoeconomics. View this article in WRRO
• Uttley L, Whyte S, Gomersall T, Ren S, Wong R, Chambers D & Tappenden P (2017) Degarelix for Treating Advanced Hormone-Dependent Prostate Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics, 35(7), 717-726. View this article in WRRO
• Tappenden P, Sadler S & Wildman M (2017) An Early Health Economic Analysis of the Potential Cost Effectiveness of an Adherence Intervention to Improve Outcomes for Patients with Cystic Fibrosis. PharmacoEconomics, 35(6). View this article in WRRO
• Carroll C, Kaltenthaler E, Hill-McManus D, Scope A, Holmes M, Rice S, Rose M, Tappenden P & Woolacott N (2017) The Type and Impact of Evidence Review Group Exploratory Analyses in the NICE Single Technology Appraisal Process. Value in Health, 20(6), 785-791. View this article in WRRO
• Atkin W, Brenner A, Martin J, Wooldrage K, Shah U, Lucas F, Greliak P, Pack K, Kralj-Hans I, Thomson A , Perera S et al (2017) The clinical effectiveness of different surveillance strategies to prevent colorectal cancer in people with intermediate-grade colorectal adenomas: a retrospective cohort analysis, and psychological and economic evaluations. Health Technology Assessment, 21(25), 1-536. View this article in WRRO
• Carroll C, Tappenden P, Rafia R, Hamilton J, Chambers D, Clowes M, Durrington P, Qureshi N & Wierzbicki AS (2017) Evolocumab for Treating Primary Hypercholesterolaemia and Mixed Dyslipidaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics, 35(5), 537-547. View this article in WRRO
• Harnan SE, Essat M, Gomersall T, Tappenden P, Pavord I, Everard M & Lawson R (2017) Exhaled nitric oxide in the diagnosis of asthma in adults: a systematic review. Clinical and Experimental Allergy, 47(3), 410-429. View this article in WRRO
• Tappenden P, Harnan S, Ren S, Thokala P, Wong R, Mukuria C, Green C, Pledge S & Tidy J (2017) Olaparib for Maintenance Treatment of BRCA 1 or 2 Mutated, Relapsed, Platinum-Sensitive Ovarian, Fallopian Tube and Peritoneal Cancer in People Whose Relapsed Disease has Responded to Platinum-Based Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics, 35(1), 97-109. View this article in WRRO
• Kaltenthaler E, Carroll C, Hill-McManus D, Scope A, Holmes M, Rice S, Rose M, Tappenden P & Woolacott N (2016) Issues Related to the Frequency of Exploratory Analyses by Evidence Review Groups in the NICE Single Technology Appraisal Process. PharmacoEconomics - Open. View this article in WRRO
• Tappenden P, Ren S, Archer R, Harvey R, Martyn-St James M, Basarir H, Stevens J, Lobo A & Hoque S (2016) A Model-Based Economic Evaluation of Biologic and Non-Biologic Options for the Treatment of Adults with Moderately-to-Severely Active Ulcerative Colitis after the Failure of Conventional Therapy. PharmacoEconomics, 34(10), 1023-1038. View this article in WRRO
• Thokala P, Simpson E, Tappenden P, Stevens J, Dickinson K, Ryder S & Harrison P (2016) Ledipasvir-Sofosbuvir for Treating Chronic Hepatitis C: A NICE Single Technology Appraisal—An Evidence Review Group Perspective. PharmacoEconomics, 34(8), 741-750. View this article in WRRO
• Sadler S, Wildman M & Tappenden P (2016) 267 Cost-effectiveness of a complex adherence intervention to improve prevention in cystic fibrosis by empowering effective self-management: an exploratory health economic evaluation using UK Registry data. Journal of Cystic Fibrosis, 15, S119-S120.
• Archer R, Tappenden P, Ren S, Martyn-St James M, Harvey R, Basarir H, Stevens J, Carroll C, Cantrell A, Lobo A & Hoque S (2016) Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262): clinical effectiveness systematic review and economic model. Health Technology Assessment, 20(39), 1-326. View this article in WRRO
• Kaltenthaler E, Carroll C, Hill-McManus D, Scope A, Holmes M, Rice S, Rose M, Tappenden P & Woolacott N (2016) The use of exploratory analyses within the National Institute for Health and Care Excellence single technology appraisal process: an evaluation and qualitative analysis.. Health Technology Assessment, 20(26), 1-48. View this article in WRRO
• Carroll C, Tappenden P, Rafia R, Hamilton J, Chambers D, Clowes M, Durrington P, Qureshi N & Wierzbicki AS (2016) Evolocumab for Treating Primary Hypercholesterolaemia and Mixed Dyslipidaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics, 35(5), 537-547.
• Gomersal T, Harnan S, Essat M, Tappenden P, Wong R, Lawson R, Pavord I & Everard ML (2016) A systematic review of fractional exhaled nitric oxide in the routine management of childhood asthma. Pediatric Pulmonology, 51(3), 316-328.
• Essat M, Tappenden P, Ren S, Bessey A, Archer R, Wong R, Lobo A & Hoque S (2016) Vedolizumab for the Treatment of Adults with Moderate-to-Severe Active Ulcerative Colitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics, 34(3), 245-257. View this article in WRRO
• Essat M, Harnan S, Gomersall T, Tappenden P, Wong R, Pavord I, Lawson R & Everard M (2016) Fractional exhaled nitric oxide for the management of asthma in adults: a systematic review. European Respiratory Society, 47(3), 751-768. View this article in WRRO
• Asaria M, Griffin S, Cookson R, Whyte S & Tappenden P (2015) Distributional cost-effectiveness analysis of health care programmes--a methodological case study of the UK Bowel Cancer Screening Programme.. Health Econ, 24(6), 742-754.
• Latimer NR, Carroll C, Wong R, Tappenden P, Venning MC & Luqmani R (2014) Rituximab in Combination with Corticosteroids for the Treatment of Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis: A NICE Single Technology Appraisal. PharmacoEconomics, 32(12), 1171-1183. View this article in WRRO
• Tappenden P & Chilcott J (2014) Avoiding and Identifying Errors and Other Threats To the Credibility of Health Economic Models. Value in Health, 17(7), A585-A585.
• Uttley L & Tappenden P (2014) Dry powder inhalers in cystic fibrosis. Current Opinion in Pulmonary Medicine, 20(6), 607-612.
• Tappenden P & Chilcott JB (2014) Avoiding and identifying errors and other threats to the credibility of health economic models.. Pharmacoeconomics, 32(10), 967-979.
• Ciani O, Davis S, Tappenden P, Garside R, Stein K, Cantrell A, Saad ED, Buyse M & Taylor RS (2014) VALIDATION OF SURROGATE ENDPOINTS IN ADVANCED SOLID TUMORS: SYSTEMATIC REVIEW OF STATISTICAL METHODS, RESULTS, AND IMPLICATIONS FOR POLICY MAKERS. International Journal of Technology Assessment in Health Care, 30(3), 312-324. View this article in WRRO
• Kaltenthaler E, Essat M, Tappenden P & Paisley S (2014) IDENTIFICATION AND REVIEW OF COST-EFFECTIVENESS MODEL PARAMETERS: A QUALITATIVE STUDY. International Journal of Technology Assessment in Health Care, 30(3), 333-340. View this article in WRRO
• Tappenden P, Harnan S, Uttley L, Mildred M, Walshaw M, Taylor C & Brownlee K (2014) The Cost Effectiveness of Dry Powder Antibiotics for the Treatment of Pseudomonas aeruginosa in Patients with Cystic Fibrosis. PHARMACOECONOMICS, 32(2), 159-172.
• Stevenson M, Tappenden P & Squires H (2014) Methods for handling uncertainty within pharmaceutical funding decisions. International Journal of Systems Science, 45(1), 60-68. View this article in WRRO
• Lord J, Willis S, Eatock J, Tappenden P, Trapero-Bertran M, Miners A, Crossan C, Westby M, Anagnostou A, Taylor S , Mavranezouli I et al (2013) Economic modelling of diagnostic and treatment pathways in National Institute for Health and Care Excellence clinical guidelines: the Modelling Algorithm Pathways in Guidelines (MAPGuide) project.. Health Technol Assess, 17(58), v-192.
• Tappenden P, Harnan S, Uttley L, Mildred M, Carroll C & Cantrell A (2013) Colistimethate sodium powder and tobramycin powder for inhalation for the treatment of chronic Pseudomonas aeruginosa lung infection in cystic fibrosis: systematic review and economic model.. Health Technol Assess, 17(56), v-181.
• Uttley L, Harnan S, Cantrell A, Taylor C, Walshaw M, Brownlee K & Tappenden P (2013) Systematic review of the dry powder inhalers colistimethate sodium and tobramycin in cystic fibrosis.. Eur Respir Rev, 22(130), 476-486.
• Asaria M, Griffin S, Cookson R, Tappenden P & Whyte S (2013) A FRAMEWORK FOR THE COST-EQUALITY ANALYSIS OF HEALTH CARE PROGRAMMES. VALUE IN HEALTH, 16(7), A426-A426.
• Kaltenthaler E, Tappenden P & Paisley S (2013) Reviewing the evidence to inform the population of cost-effectiveness models within health technology assessments. Value in Health, 16(5), 830-836. View this article in WRRO
• Simpson EL, Fitzgerald P, Evans P, Tappenden P, Kalita N, Reckless JPD & Bakhai A (2013) Bivalirudin for the treatment of ST-segment elevation myocardial infarction: a NICE single technology appraisal.. Pharmacoeconomics, 31(4), 269-275.
• Hoyle M, Crathorne L, Peters J, Jones-Hughes T, Cooper C, Napier M, Tappenden P & Hyde C (2013) The clinical effectiveness and cost-effectiveness of cetuximab (mono- or combination chemotherapy), bevacizumab (combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy (review of technology appraisal No.150 and part review of technology appraisal No. 118): a systematic review and economic model.. Health Technol Assess, 17(14), 1-237.
• Sharp L, Tilson L, Whyte S, Ceilleachair AO, Walsh C, Usher C, Tappenden P, Chilcott J, Staines A, Barry M & Comber H (2013) Using resource modelling to inform decision making and service planning: the case of colorectal cancer screening in Ireland.. BMC Health Serv Res, 13, 105. View this article in WRRO
• Rathbone J, Kaltenthaler E, Richards A, Tappenden P, Bessey A & Cantrell A (2013) A systematic review of eculizumab for atypical haemolytic uraemic syndrome (aHUS).. BMJ Open, 3(11), e003573. View this article in WRRO
• Tappenden P, Chilcott J, Brennan A, Squires H, Glynne-Jones R & Tappenden J (2013) Using Whole Disease Modeling to Inform Resource Allocation Decisions: Economic Evaluation of a Clinical Guideline for Colorectal Cancer Using a Single Model. Value in Health.
• Tappenden P, Chilcott J, Brennan A, Squires H & Stevenson M (2012) Whole disease modeling to inform resource allocation decisions in cancer: a methodological framework.. Value Health, 15(8), 1127-1136.
• Tappenden P, Campbell F, Rawdin A, Wong R & Kalita N (2012) The clinical effectiveness and cost-effectiveness of home-based, nurse-led health promotion for older people: a systematic review.. Health Technol Assess, 16(20), 1-72.
• Sharp L, Tilson L, Whyte S, O'Ceilleachair A, Walsh C, Usher C, Tappenden P, Chilcott J, Staines A, Barry M & Comber H (2012) Cost-effectiveness of population-based screening for colorectal cancer: a comparison of guaiac-based faecal occult blood testing, faecal immunochemical testing and flexible sigmoidoscopy.. Br J Cancer, 106(5), 805-816. View this article in WRRO
• Shabaruddin FH, Elliott RA, Tappenden P & Payne K (2012) Assessing the costs and benefits of a pharmacogenetic test to reduce the incidence of adverse events. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 21(1), 118-118.
• Delea TE, Tappenden P, Sofrygin O, Browning D, Amonkar MM, Karnon J, Walker MD & Cameron D (2012) Cost-effectiveness of lapatinib plus capecitabine in women with HER2+ metastatic breast cancer who have received prior therapy with trastuzumab.. Eur J Health Econ, 13(5), 589-603.
• Tilson L, Sharp L, Usher C, Walsh C, Whyte S, O'Ceilleachair A, Stuart C, Mehigan B, Kennedy MJ, Tappenden P , Chilcott J et al (2012) Cost of care for colorectal cancer in Ireland: A health care payer perspective. European Journal of Health Economics, 13(4), 511-524.
• Shabaruddin FH, Elliott RA, Tappenden P & Payne K (2011) COST-EFFECTIVENESS OF USING THE UGT1A1 PHARMACOGENETIC TEST TO REDUCE THE INCIDENCE OF IRINOTECAN CHEMOTHERAPY-RELATED FEBRILE NEUTROPAENIA. VALUE IN HEALTH, 14(7), A251-A252.
• Shabaruddin FH, Elliott RA, Tappenden P & Payne K (2011) ECONOMIC EVALUATION OF THE UGT1A1 PHARMACOGENETIC TEST TO INFORM DOSE SELECTION OF IRINOTECAN-BASED CHEMOTHERAPY. VALUE IN HEALTH, 14(7), A252-A252.
• Squires H, Tappenden P, Cooper K, Carroll C, Logan R & Hind D (2011) Cost-effectiveness of aspirin, celecoxib, and calcium chemoprevention for colorectal cancer. Clinical Therapeutics, 33(9), 1289-1305.
• Whyte S, Walsh C & Chilcott J (2011) Bayesian Calibration of a Natural History Model with Application to a Population Model for Colorectal Cancer. Medical Decision Making, 31(4), 625-641.
• Jackson RJ, Cooper KL, Tappenden P, Rees A, Simpson EL, Read RC & Nicholson KG (2011) Oseltamivir, zanamivir and amantadine in the prevention of influenza: a systematic review.. J Infect, 62(1), 14-25.
• Papaioannou D, Cooper KL, Carroll C, Hind D, Squires H, Tappenden P & Logan RF (2011) Antioxidants in the chemoprevention of colorectal cancer and colorectal adenomas in the general population: a systematic review and meta-analysis.. Colorectal Dis, 13(10), 1085-1099.
• Bending MW, Trueman P, Lowson KV, Pilgrim H, Tappenden P, Chilcott J & Tappenden J (2010) Estimating the direct costs of bowel cancer services provided by the National Health Service in England.. Int J Technol Assess Health Care, 26(4), 362-369.
• Cooper K, Squires H, Carroll C, Papaioannou D, Booth A, Logan RF, Maguire C, Hind D & Tappenden P (2010) Chemoprevention of colorectal cancer: systematic review and economic evaluation.. Health Technol Assess, 14(32), 1-206.
• Sofrygin O, Delea TE, Tappenden P, Karnon J, Browning D, Amonkar M, Lykopoulos K & Cameron DA (2010) Cost-effectiveness of lapatinib plus capecitabine (LAP plus C) versus capecitabine alone (C-only) or trastuzumab plus capecitabine (TZ plus C) in women with HER2-positive metastatic breast cancer (MBC) who have received prior therapy with trastuzumab (TZ) from the UK National Health Service (NHS) perspective. JOURNAL OF CLINICAL ONCOLOGY, 28(15).
• Carroll C, Cooper K, Papaioannou D, Hind D, Pilgrim H & Tappenden P (2010) Supplemental Calcium in the Chemoprevention of Colorectal Cancer: A Systematic Review and Meta-Analysis. CLIN THER, 32(5), 789-803.
• Chilcott J, Tappenden P, Rawdin A, Johnson M, Kaltenthaler E, Paisley S, Papaioannou D & Shippam A (2010) Avoiding and identifying errors in health technology assessment models: qualitative study and methodological review.. Health Technol Assess, 14(25), iii-107.
• Oakley JE, Brennan A, Tappenden P & Chilcott J (2010) Simulation sample sizes for Monte Carlo partial EVPI calculations.. J Health Econ, 29(3), 468-477. View this article in WRRO
• Carroll C, Cooper K, Papaioannou D, Hind D, Tappenden P, Pilgrim H & Booth A (2010) Meta-analysis: folic acid in the chemoprevention of colorectal adenomas and colorectal cancer.. Aliment Pharmacol Ther, 31(7), 708-718.
• Bending MW, Trueman P, Lowson KV, Pilgrim H, Tappenden P, Chilcott J & Tappenden J (2010) Estimating the direct costs of bowel cancer services provided by the National Health Service in England. International Journal of Technology Assessment in Health Care, 26(4), 362-369.
• McCabe C, Chilcott J, Claxton K, Tappenden P, Cooper C, Roberts J, Cooper N & Abrams K (2010) Continuing the multiple sclerosis risk sharing scheme is unjustified.. BMJ, 340, c1786.
• Madan J, Rawdin A, Stevenson M & Tappenden P (2010) A rapid-response economic evaluation of the UK NHS Cancer Reform Strategy breast cancer screening program extension via a plausible bounds approach.. Value Health, 13(2), 215-221.
• Tappenden P, Saccardi R, Confavreux C, Sharrack B, Muraro PA, Mancardi GL, Kozak T, Farge-Bancel D, Madan J, Rafia R , Akehurst R et al (2010) Autologous haematopoietic stem cell transplantation for secondary progressive multiple sclerosis: an exploratory cost-effectiveness analysis.. Bone Marrow Transplant, 45(6), 1014-1021.
• Sharp L, Tilson L, Whyte S, O'Ceilleachair A, Walsh C, Usher C, Tappenden P, Chilcott J, Staines A, Comber H & Barry M (2009) COST-EFFECTIVENESS OF A POPULATION-BASED COLORECTAL CANCER SCREENING PROGRAMME IN IRELAND. VALUE HEALTH, 12(7), A280-A280.
• Pilgrim H, Tappenden P, Chilcott J, Bending M, Trueman P, Shorthouse A & Tappenden J (2009) The costs and benefits of bowel cancer service developments using discrete event simulation. J OPER RES SOC, 60(10), 1305-1314.
• Tappenden P, Chilcott J, Brennan A & Pilgrim H (2009) Systematic review of economic evidence for the detection, diagnosis, treatment, and follow-up of colorectal cancer in the United Kingdom.. Int J Technol Assess Health Care, 25(4), 470-478.
• Whyte S, Walsh C, Sharp L, O'Ceilleachair A, Tilson L, Usher C, Chilcott J, Tappenden P, Staines A, Comber H & Barry M (2009) PMC46 BAYESIAN CALIBRATION OF A NATURAL HISTORY MODEL FOR COLORECTAL CANCER. Value in Health, 12(7), A395-A395.
• Hind D, Tappenden P, Peters J & Kenjegalieva K (2009) Varenicline in the management of smoking cessation: a single technology appraisal.. Health Technol Assess, 13 Suppl 2, 9-13.
• Delea T, Sofrygin O, Tappenden P, Browning D, Amonkar MM, Karnon J & Lykopoulos K (2009) COST-EFFECTIVENESS (CE) ANALYSIS OF ERBB2-TARGETED THERAPIES IN WOMEN WITH TRASTUZUMAB (TZ)-REFRACTORY ERBB2+METASTATIC BREAST CANCER (MBC) AND LIMITED EXPOSURE TO PRIOR CHEMOTHERAPY (CT). VALUE HEALTH, 12(3), A49-A49.
• Tappenden P, Jackson R, Cooper K, Rees A, Simpson E, Read R & Nicholson K (2009) Amantadine, oseltamivir and zanamivir for the prophylaxis of influenza (including a review of existing guidance no. 67): a systematic review and economic evaluation.. Health Technol Assess, 13(11), iii-246.
• Tappenden P, McCabe C, Chilcott J, Simpson E, Nixon R, Madan J, Fisk JD & Brown M (2009) Cost-effectiveness of disease-modifying therapies in the management of multiple sclerosis for the Medicare population.. Value Health, 12(5), 657-665.
• Kerner JF, Cazap E, Yach D, Pierotti MA, Daidone MG, De Blasio P, Geary P, Schacter B, Sant M, Habbema JDF , Sankaranarayanan R et al (2009) Comprehensive cancer control-research & development: Knowing what we do and doing what we know. Tumori, 95(5), 610-622.
• Pickin M, Cooper CL, Chater T, O'Hagan A, Abrams KR, Cooper NJ, Boggild M, Palace J, Ebers G, Chilcott JB , Tappenden P et al (2009) The Multiple Sclerosis Risk Sharing Scheme Monitoring Study--early results and lessons for the future.. BMC Neurol, 9, 1. View this article in WRRO
• Kaltenthaler E, Tappenden P, Booth A & Akehurst R (2008) Comparing methods for full versus single technology appraisal: a case study of docetaxel and paclitaxel for early breast cancer.. Health Policy, 87(3), 389-400.
• DeLea T, Tappenden P, Sofrygin O, Karnon J, Amonkar M, Browning D, Rudge HJ & Walker MD (2008) Cost-effectiveness (CE) of lapatinib plus capecitabine (L+C) in women with HER2+ metastatic breast cancer (MBC) who received prior therapy with trastuzumab (TZ) based on updated survival data from EGF100151.. J Clin Oncol, 26(15_suppl), 6559.
• DeLea T, Tappenden P, Sofrygin O, Karnon J, Amonkar M, Browning D, Rudge HJ & Walker MD (2008) Cost-effectiveness (CE) of lapatinib plus capecitabine (L plus C) in women with HER2+metastatic breast cancer (MBC) who received prior therapy with trastuzumab (TZ) based on updated survival data from EGF100151. JOURNAL OF CLINICAL ONCOLOGY, 26(15).
• Sofrygin O, Delea T, Tappenden P, Karnon J, Amonkar MM & Walker M (2008) Validity of proportional hazards (PH) Weibull models for analyzing progression free survival (PFS) and overall survival (OS) in patients with trastuzumab (TZ)-refractory ERBB2+(HER2+) metastatic breast cancer (MBC) receiving lapatinib plus capecitabine (L+C) versus capecitabine only (C-only). VALUE HEALTH, 11(3), A57-A57.
• Hind D, Tappenden P, Tumur I, Eggington S, Sutcliffe P & Ryan A (2008) The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation.. Health Technol Assess, 12(15), iii-162.
• Karnon J, McIntosh A, Dean J, Bath P, Hutchinson A, Oakley J, Thomas N, Pratt P, Freeman-Parry L, Karsh B-T , Gandhi T et al (2008) Modelling the expected net benefits of interventions to reduce the burden of medication errors.. J Health Serv Res Policy, 13(2), 85-91. View this article in WRRO
• Garthwaite PH, Chilcott JB, Jenkinson DJ & Tappenden P (2008) Use of expert knowledge in evaluating costs and benefits of alternative service provisions: a case study.. Int J Technol Assess Health Care, 24(3), 350-357.
• Parkin DM, Tappenden P, Olsen AH, Patnick J & Sasieni P (2008) Predicting the impact of the screening programme for colorectal cancer in the UK.. J Med Screen, 15(4), 163-174.
• Karnon J, Goyder E, Tappenden P, McPhie S, Towers I, Brazier J & Madan J (2007) A review and critique of modelling in prioritising and designing screening programmes.. Health technology assessment (Winchester, England), 11(52).
• Karnon J, Goyder E, Tappenden P, McPhie S, Towers I, Brazier J & Madan J (2007) A review and critique of modelling in prioritising and designing screening programmes. HEALTH TECHNOL ASSES, 11(52), 1-+. View this article in WRRO
• Tappenden P, Jones R, Paisley S & Carroll C (2007) The cost-effectiveness of bevacizumab in the first-line treatment of metastatic colorectal cancer in England and Wales.. Eur J Cancer, 43(17), 2487-2494.
• Tappenden P, Chilcott J, Eggington S, Patnick J, Sakai H & Karnon J (2007) Option appraisal of population-based colorectal cancer screening programmes in England.. Gut, 56(5), 677-684.
• Karnon J, McIntosh A, Dean J, Bath P, Hutchinson A, Oakley J, Thomas N, Pratt P, Freeman-Parry L, Karsh BT , Gandhi T et al (2007) A prospective hazard and improvement analytic approach to predicting the effectiveness of medication error interventions. SAFETY SCI, 45(4), 523-539. View this article in WRRO
• Tappenden P, Jones R, Paisley S & Carroll C (2007) Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer.. Health technology assessment (Winchester, England), 11(12).
• Tappenden P, Jones R, Paisley S & Carroll C (2007) Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer.. Health technology assessment (Winchester, England), 11(12).
• Tappenden P, Jones R, Paisley S & Carroll C (2007) Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer.. Health Technol Assess, 11(12), 1-iv.
• Karnon J, Goyder E, Tappenden P, McPhie S, Towers I, Brazier J & Madan J (2007) A review and critique of modelling in prioritising and designing screening programmes.. Health technology assessment (Winchester, England), 11(52).
• Tappenden P, Brazier J, Ratcliffe J & Chilcott J (2007) A stated preference binary choice experiment to explore NICE decision making.. Pharmacoeconomics, 25(8), 685-693.
• Eggington S, Tappenden P, Pandor A, Paisley S, Saunders M, Seymour M, Sutcliffe P & Chilcott J (2006) Cost-effectiveness of oxaliplatin and capecitabine in the adjuvant treatment of stage III colon cancer.. Br J Cancer, 95(9), 1195-1201. View this article in WRRO
• Pandor A, Eggington S, Paisley S, Tappenden P & Sutcliffe P (2006) The clinical and cost-effectiveness of oxaliplatin and capecitabine for the adjuvant treatment of colon cancer: systematic review and economic evaluation.. Health technology assessment (Winchester, England), 10(41).
• Pandor A, Eggington S, Paisley S, Tappenden P & Sutcliffe P (2006) The clinical and cost-effectiveness of oxaliplatin and capecitabine for the adjuvant treatment of colon cancer: systematic review and economic evaluation.. Health Technol Assess, 10(41), iii-185. View this article in WRRO
• Tappenden P, Chilcott J, Ward S, Eggington S, Hind D & Hummel S (2006) Methodological issues in the economic analysis of cancer treatments.. Eur J Cancer, 42(17), 2867-2875.
• Chilcott J, Tappenden P, Lloyd Jones M, Wight J, Forman K, Wray J & Beverley C (2004) The economics of routine antenatal anti-D prophylaxis for pregnant women who are rhesus negative.. BJOG, 111(9), 903-907.
• Jones ML, Wray J, Wight J, Chilcott J, Forman K, Tappenden P & Beverley C (2004) A review of the clinical effectiveness of routine antenatal anti-D prophylaxis for rhesus-negative women who are pregnant.. BJOG, 111(9), 892-902.
• Tappenden P, Chilcott JB, Eggington S, Oakley J & McCabe C (2004) Methods for expected value of information analysis in complex health economic models: developments on the health economics of interferon-beta and glatiramer acetate for multiple sclerosis.. Health Technol Assess, 8(27), iii-78. View this article in WRRO
• Chilcott J, McCabe C, Tappenden P, O'Hagan A, Cooper NJ, Abrams K, Claxton K, Miller DH & Cost Effectiveness of Multiple Sclerosis Therapies Study Group (2003) Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis. Commentary: evaluating disease modifying treatments in multiple sclerosis.. BMJ, 326(7388), 522.
• Chilcott J, Brennan A, Booth A, Karnon J & Tappenden P (2003) The role of modelling in prioritising and planning clinical trials.. Health technology assessment (Winchester, England), 7(23). View this article in WRRO
• Chilcott J, Lloyd Jones M, Wight J, Forman K, Wray J, Beverley C & Tappenden P (2003) A review of the clinical effectiveness and cost-effectiveness of routine anti-D prophylaxis for pregnant women who are rhesus-negative.. Health Technol Assess, 7(4), iii-62. View this article in WRRO
• Richards RG, Sampson FC, Beard SM & Tappenden P (2002) A review of the natural history and epidemiology of multiple sclerosis: Implications for resource allocation and health economic models. Health Technology Assessment, 6(10). View this article in WRRO
• Chilcott J, Tappenden P, Jones ML & Wight JP (2001) A systematic review of the clinical effectiveness of pioglitazone in the treatment of type 2 diabetes mellitus.. Clin Ther, 23(11), 1792-1823.
• Chilcott J, Wight J, Jones ML & Tappenden P (2001) The clinical effectiveness and cost-effectiveness of pioglitazone for type 2 diabetes mellitus: A rapid and systematic review. Health Technology Assessment, 5(19). View this article in WRRO
• Lister J, Paisley S, Carroll C & Tappenden P () Empirical Testing of Alternative Search Methods to Retrieve Utility Values for Health Economic Modelling. PharmacoEconomics.
• Tappenden P, Hardiman O, Kwon S-H, Mon-Yee M, Galvin M & McDermott C () A Model-Based Economic Evaluation of Hypothetical Treatments for Amyotrophic Lateral Sclerosis in the UK: Implications for Pricing of New and Emerging Health Technologies. PharmacoEconomics.
• Jin H, Tappenden P, Ling X, Robinson S & Byford S () A systematic review of whole disease models for informing healthcare resource allocation decisions. PLOS ONE, 18(9), e0291366-e0291366.
• Jin H, Tappenden P, MacCabe JH, Robinson S, McCrone P & Byford S () Cost and health impacts of adherence to the National Institute for Health and Care Excellence schizophrenia guideline recommendations. The British Journal of Psychiatry, 1-6.
• Hind D, Tappenden P, Peters J & Kenjegalieva K () Varenicline in the management of smoking cessation: a single technology appraisal. Health Technology Assessment, 13(Suppl 2), 9-13.
• Wildman M, O'Cathain A, Maguire C, Arden M, Hutchings M, Bradley J, Walters S, Whelan P, Ainsworth J, Buchan I , Mandefield L et al () Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax. View this article in WRRO
• Wildman M, Hutchings M, Arden M, O'Cathain A, Drabble S, Walters SJ, Tappenden P, Beever D, Whelan P, Bradley J , Cantrill H et al () Development and evaluation of an intervention to support Adherence to treatment in adults with Cystic Fibrosis: A randomised controlled trial and parallel process evaluation protocol. View this article in WRRO
• Campbell F, Holmes M, Everson-Hock E, Davis S, Buckley Woods H, Anokye N, Tappenden P & Kaltenthaler E () A systematic review and economic evaluation of exercise referral schemes in primary care: a short report. Health Technology Assessment, 19(60), 1-110. View this article in WRRO
• Harnan SE, Tappenden P, Essat M, Gomersall T, Minton J, Wong R, Pavord I, Everard M & Lawson R () Measurement of exhaled nitric oxide concentration in asthma: a systematic review and economic evaluation of NIOX MINO, NIOX VERO and Nobreath. Health Technology Assessment, 19(82), 1-330. View this article in WRRO
• Cooper K, Tappenden P, Cantrell A & Ennis K () A systematic review of meta-analyses assessing the validity of tumour response endpoints as surrogates for progression-free or overall survival in cancer. British Journal of Cancer.
• Wildman MJ, O’Cathain A, Hind D, Maguire C, Arden MA, Hutchings M, Bradley J, Walters SJ, Whelan P, Ainsworth J , Tappenden P et al () An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research, 9(11), 1-146.

Chapters

• Tappenden P (2014) Problem Structuring for Health Economic Model Development, Encyclopedia of Health Economics (pp. 168-179). Elsevier

Conference proceedings papers

• Needham KJ, Tappenden P, Gillespie D & Whyte S (2023) Model-based Evaluations of the Cost-effectiveness of Interventions for Lung Cancer: A Systematic Review. JOURNAL OF THORACIC ONCOLOGY, Vol. 18(11) (pp S134-S134)
• Lister J, Paisley S, Tappenden P & Carroll C (2023) IDENTIFICATION OF HEALTH STATE UTILITY VALUES FOR HEALTH ECONOMIC MODELS: EMPIRICAL TESTING OF ALTERNATIVE SEARCH METHODS. VALUE IN HEALTH, Vol. 26(12) (pp S174-S175)
• Wheaton L, Poad H, Tappenden P & Bujkiewicz S (2023) BAYESIAN META-ANALYSIS OF DATA FROM TRIALS OF MIXED PATIENT POPULATIONS TO INFORM HEALTH ECONOMIC MODELS FOR PATIENTS HARBORING A PREDICTIVE BIOMARKER. VALUE IN HEALTH, Vol. 26(12) (pp S425-S425)
• Lister J, Paisley S, Tappenden P & Carroll C (2023) A SCOPING REVIEW OF HEALTH TECHNOLOGY ASSESSMENT AGENCY (HTA) AND HEALTH ECONOMIC (HE) MODELLING GUIDELINES FOR IDENTIFICATION OF HEALTH ECONOMIC MODEL INPUTS. VALUE IN HEALTH, Vol. 26(12) (pp S375-S375)
• Alshreef A, Latimer N, Tappenden P, McKane W, Hughes DA & Dixon S (2022) A METHODOLOGICAL FRAMEWORK TO ACCOUNT FOR THE IMPACT OF NON-ADHERENCE ON THE COST-EFFECTIVENESS OF CHRONIC MEDICATIONS. VALUE IN HEALTH, Vol. 25(7) (pp S520-S520)
• Alshreef A, Latimer N, Tappenden P, McKane W, Fotheringham J & Dixon S (2022) A CASE STUDY ASSESSING THE COST-EFFECTIVENESS OF MAINTENANCE IMMUNOSUPPRESSIVE THERAPY FOR KIDNEY TRANSPLANTATION IN ADULTS: ACCOUNTING FOR NON-ADHERENCE USING DATA FROM A RANDOMISED TRIAL AND THE REAL WORLD WITHIN A DECISION-ANALYTIC MODEL. VALUE IN HEALTH, Vol. 25(7) (pp S529-S529)
• Srivastava T, Latimer NR & Tappenden P (2020) ESTIMATION OF TRANSITION PROBABILITIES FOR STATE-TRANSITION MODELS: A REVIEW OF NICE APPRAISALS. VALUE IN HEALTH, Vol. 23 (pp S615-S616)
• Alshreef A, Latimer N, Tappenden P, McKane W, Wong R, Hughes D, Wailoo A, White I, Fotheringham J & Dixon S (2018) Adjusting the causal effects of treatments in the presence of patient non-adherence: a systematic review of methodological papers. European Society for Patient Adherence, Compliance and Persistence, Dublin, 29 November 2018 - 1 December 2018.
• Tappenden P, Wang Y, Burman J, Kazmi M, Saccardi R, Bermejo I, Harvey R, Badoglio M, Farge D, Sharrack B & Snowden J (2017) Evaluating the cost-effectiveness of autologous haematopoietic stem cell transplantation (aHSCT) versus disease-modifying therapy in multiple sclerosis using a matching-adjusted indirect comparison (MAIC). BONE MARROW TRANSPLANTATION, Vol. 52 (pp S41-S41)
• Kaltenthaler E, Carroll C, Hill-McManus D, Scope A, Holmes M, Rice S, Rose M, Tappenden P & Woolacott N (2016) Issues Related to the Frequency of Exploratory Analyses by Evidence Review Groups in the Nice Single Technology Appraisal Process. Value in Health, Vol. 19(7) (pp A490-A490)
• Carroll C, Kaltenthaler E, Tappenden P, Hill-McManus D, Scope A, Holmes M, Rice S, Rose M & Woolacott N (2016) The Role and Impact of Evidence Review Group Analyses in the Nice Single Technology Assessment (STA) Process. Value in Health, Vol. 19(7) (pp A468-A469)
• Goodall M, Tosh J, Alshreef A & Tappenden P (2016) Conceptual Modelling for Cost-Effectiveness Analysis of Intravitreal Therapy with Ranibizumab, Aflibercept or Bevacizumab for Macular Oedema Due to Central Retinal Vein Occlusion. Value in Health, Vol. 19(7) (pp A366-A366) View this article in WRRO
• Harnan S, Essat M, Gomersall T, Tappenden P, Wong R, Lawson R, Pavord I & Everard M (2015) Exhaled Nitric Oxide For The Diagnosis Of Asthma In Adults And Children: A Systematic Review. Value in Health, Vol. 18(7) (pp A345-A345)
• Tappenden P, Harnan S, Uttley L, Mildred M, Taylor CJ, Brownlee K & Walshaw M (2013) The Cost-Effectiveness of Dry Powder Antibiotics for the Treatment of Pseudomonas Aeruginosa in Patients with Cystic Fibrosis. Value in Health, Vol. 16(7) (pp A372-A372)
• Ciani O, Davis S, Tappenden P, Garside R, Stein K, Cantrell A, Saad E, Buyse M & Taylor R (2013) VALIDATION OF SURROGATE ENDPOINTS IN ADVANCED SOLID TUMOURS: SYSTEMATIC REVIEW OF STATISTICAL METHODS, RESULTS, AND IMPLICATIONS FOR POLICY MAKERS. VALUE IN HEALTH, Vol. 16(7) (pp A327-A327)
• Harnan SE, Uttley L, Cantrell A, Taylor CJ, Walshaw M, Brownlee K & Tappenden P (2013) SYSTEMATIC REVIEW OF COLISTIMETHATE SODIUM DRY POWDER AND TOBRAMYCIN DRY POWDER ANTIBIOTICS FOR PSEUDOMONAS AERUGINOSA LUNG INFECTION IN CYSTIC FIBROSIS. VALUE IN HEALTH, Vol. 16(7) (pp A367-A367)
• Kaltenthaler E, Rathbone J, Tappenden P, Bessey A & Cantrell A (2012) ISSUES IN THE SYSTEMATIC REVIEW OF DRUGS FOR RARE DISEASES: A CASE STUDY OF ECULIZUMAB FOR AHUS. VALUE IN HEALTH, Vol. 15(7) (pp A455-A455)
• Tappenden P, Brennan A, Chilcott J & Squires H (2011) USING WHOLE DISEASE MODELLING TO INFORM ECONOMIC RECOMMENDATIONS FOR THE DETECTION, DIAGNOSIS, TREATMENT AND FOLLOW-UP OF COLORECTAL CANCER. VALUE IN HEALTH, Vol. 14(7) (pp A469-A470)
• Tappenden P, Brennan A, Chilcott J & Squires H (2011) A METHODOLOGICAL FRAMEWORK FOR DEVELOPING MODELS OF WHOLE DISEASE AREAS TO INFORM RESOURCE ALLOCATION DECISIONS. VALUE IN HEALTH, Vol. 14(7) (pp A243-A243)
• Delea TE, Tappenden P, Sofrygin O, Karnon J, Amonkar M, Browning D, Rudge H & Walker M (2007) Cost-effectiveness (CE) of lapatinib plus capecitabine (L plus C) in women with ErbB2+(HER2+) metastatic breast cancer (MBC) who have received prior therapy with trastuzumab (TZ) from the United Kingdom (UK) National Health Service (NHS) perspective. EJC SUPPLEMENTS, Vol. 5(4) (pp 225-225)

Scholarly editions

• Claxton K, Eggington S, Ginnelly L, Griffin S, McCabe C, Philips Z, Tappenden P & Wailoo A A Pilot Study of Value of Information Analysis to Support Research Recommendations for the National Institute for Health and Clinical Excellence.
• Tappenden P, Brazier J & Ratcliffe J Does the National Institute for Health and Clinical Excellence take account of factors such as uncertainty and equity as well as incremental cost-effectiveness in commissioning health care services? A binary choice experiment.

Posters

• Rathbone J, Kaltenthaler E, Tappenden P, Bessey A & Cantrell A Issues in the systematic review of drugs for rare diseases: A case study of Eculizumab for AHUS (2012).
• Harnan S, Essat M, Gomersall T, Tappenden P, Wong R, Lawson R, Pavord I & Everard M Exhaled nitric oxide for the diagnosis of asthma in children and adults: a systematic review.
• Kaltenthaler E, Tappenden P & Paisley S Reviewing the evidence used in cost effectiveness models in health technology assessment: a qualitative investigation of current concerns.
• Tappenden P, Brennan A, Chilcott J & Squires H Using Whole Disease Modelling to inform economic recommendations for the detection, diagnosis, treatment and followup of colorectal cancer.

Preprints

• Umemneku-Chikere CM, Wheaton L, Poad H, Ray D, Andrade IC, Khan S, Tappenden P, Abrams KR, Owen RK & Bujkiewicz S (2023) Individual participant data from digital sources informed and improved precision in the evaluation of predictive biomarkers in Bayesian network meta-analysis, arXiv.